In this regard, our present finding that DDR1 affects both the AKT and the ERK1/2 pathways is particularly relevant, as IR/IGF-1R inhibitors proposed for cancer treatment are generally more effective in blocking the AKT pathway than inhibiting the ERK pathway, and may actually stimulate this pathway in certain models [42–44]. Here, MAPK3 is linked to cancer.